Ox40 Antibody (OX86): sc-53104
- Ox40 Antibody (OX86) is a rat monoclonal IgG1 provided at 200 µg/ml
- raised against OX40 of mouse origin
- recommended for detection of Ox40 cell surface antigen of mouse origin by IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Ox40 Antibody (OX86). This work is in progress.
QUICK LINKS
Ox40 Antibody (OX86) is a rat monoclonal IgG1 antibody that detects Ox40 in mouse samples through applications such as immunofluorescence (IF) and flow cytometry (FCM). Ox40, also known as CD134 or Ox40R, plays a crucial role in the immune response by regulating the activation and differentiation of CD4+ T lymphocytes. anti-Ox40 antibody (OX86) recognizes a protein primarily located on the surface of activated CD4+ T cells, where Ox40 interacts with its ligand, Ox40L, predominantly expressed on activated B cells. The engagement of Ox40 with Ox40L provides a vital costimulatory signal that enhances T cell activation, promoting effective immune responses. This interaction is particularly important for the generation of robust T helper cell responses, which are essential for orchestrating adaptive immunity and ensuring the body can effectively combat infections and maintain tissue homeostasis. Given Ox40′s significant role in T cell regulation and involvement in various immunological conditions, including autoimmune diseases and inflammatory responses, Ox40 (OX86) monoclonal antibody serves as a valuable tool for researchers studying T cell dynamics and therapeutic interventions in these areas.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Ox40 Antibody (OX86) References:
- OX40 agonists for cancer treatment: a patent review. | Cebada, J., et al. 2021. Expert Opin Ther Pat. 31: 81-90. PMID: 32945223
- The OX40/OX40L Axis Regulates T Follicular Helper Cell Differentiation: Implications for Autoimmune Diseases. | Fu, N., et al. 2021. Front Immunol. 12: 670637. PMID: 34234777
- OX40 and 4-1BB delineate distinct immune profiles in sarcoma. | Melake, MJ., et al. 2022. Oncoimmunology. 11: 2066050. PMID: 35558159
- Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. | Zhu, J., et al. 2022. Nat Commun. 13: 7466. PMID: 36463242
- The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity. | Yu, J., et al. 2023. Cell Mol Immunol. 20: 1445-1456. PMID: 37932534
- Recently activated CD4 T cells in tuberculosis express OX40 as a target for host-directed immunotherapy. | Gress, AR., et al. 2023. Nat Commun. 14: 8423. PMID: 38110410
- Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis. | Rewerska, B., et al. 2024. J Allergy Clin Immunol Glob. 3: 100195. PMID: 38187863
- OX40/OX40 ligand and its role in precision immune oncology. | Thapa, B., et al. 2024. Cancer Metastasis Rev. 43: 1001-1013. PMID: 38526805
- The Role of OX40-OX40L Axis in the Pathogenesis of Atopic Dermatitis. | Schettini, N., et al. 2025. Dermatitis. 36: 28-36. PMID: 38700255
- Research progress in OX40/OX40L in allergic diseases. | Song, R., et al. 2024. Int Forum Allergy Rhinol. 14: 1921-1928. PMID: 39404736
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ox40 Antibody (OX86) | sc-53104 | 200 µg/ml | $316.00 | |||
Ox40 Antibody (OX86) FITC | sc-53104 FITC | 200 µg/ml | $330.00 | |||
Ox40 Antibody (OX86) PE | sc-53104 PE | 200 µg/ml | $343.00 |